Categorynews

Stallergenes Greer Will Be at 2019 EAACI Congress and Present the Results of Its Phase III House Dust Mites Tablet Trial

May 31, 2019 Off By BusinessWire

LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/EAACI2019?src=hash" target="_blank"gt;#EAACI2019lt;/agt;–Stallergenes Greer today announced that house dust mite (HDM) induced
allergic rhinitis, its treatment with sublingual tablets and the
benefits of allergen immunotherapy (AIT) for patients will be presented
at the annual EAACI Congress to be held in Lisbon (Portugal) from June
1-5 2019. Scientific presentations will detail the results of its Phase
III clinical trial evaluating the efficacy and safety of its sublingual
allergy immunotherapy tablet STAGR320 for the treatment of house dust
mite-induced allergic rhinitis.

« House dust mite-induced allergic rhinitis is a highly prevalent
chronic illness which often has a negative impact on overall health,
sleep, work and leisure activities. Detailed results of our STAGR320
trial will be shared at EAACI 2019. These results illustrate
Stallergenes Greer’s determination to develop a large portfolio of
treatment options, including sublingual tablet treatments. We are
committed to advancing research to improve the lives of people with
allergies » stated Michele Antonelli, Chief Executive Officer of
Stallergenes Greer.

Poster session: June 2, 2019 10:30 am – 12:00 pm

« EFFICACY OF A 300IR HOUSE DUST MITE TABLET IS CONSISTENT WHEN
EVALUATED BY THE PROPORTION OF SYMPTOM-CONTROLLED DAYS: RESULTS OF A
LARGE RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTRE TRIAL »

Authors: P. Demoly, P. Creticos, P.
Gevaert, K De Blay, K. Kowal, M. Le Gall, N. Nenasheva, G. Passalacqua,
O. Pfaar, M. Tortajada-Girbés, V. Vidal, T.Casale, J. Corren

Poster session: June 2, 2019 10:30 am -12:00 pm

« QUALITY OF LIFE IN PATIENTS WITH HOUSE DUST MITE-ASSOCIATED ALLERGIC
RHINITIS TREATED WITH 300IR HOUSE DUST MITE SUBLINGUAL TABLET: RESULTS
OF A LARGE MULTICENTRE CLINICAL TRIAL »

Authors: T. Casale, P. Creticos, F. De
Blay, P. Gevaert, K. Kowal, M. Le Gall, N. Nenasheva, G. Passalacqua, O.
Pfaar, M. Tortajada-Girbés, C. Vidal, P. Demoly, J. Corren

Poster session: June 4, 2019 : 12:00 am -13:30 pm

« ‘BLOCKERS’ CAN BENEFIT FROM 300IR HOUSE DUST MITE TABLET – RESULTS OF
A LARGE MULTICENTRE CLINICAL TRIAL IN HOUSE DUST MITE INDUCED ALLERGIC
RHINITIS PATIENTS »

Authors: P. Demoly, P. Creticos, F. De
Blay, P. Gevaert, K. Kowal, M. Le Gall, N. Nenasheva, G. Passalacqua, O.
Pfaar, M. Tortajada-Girbés, C. Vidal, T. Casale, J. Corren

ABOUT THE STAGR320 PHASE III CLINICAL TRIAL

The phase III trial was a global, multi-center, randomized, double-blind
and placebo controlled study. It evaluated the efficacy and safety of
STAGR320 at a daily dose of 300IR administered to adult and adolescent
patients aged 12-65 with HDM-induced allergic rhinitis. Patients who
experienced HDM associated allergic rhinitis for at least one year, who
were sensitized to D. pteronyssinus and/or D. farinae mites as
determined by a skin prick test and HDM-specific serum immunoglobulin E,
were eligible for participation.

This was the largest phase III clinical trial conducted to evaluate the
treatment of house dust mite allergy in adult and adolescent patients.
The study recruited more than 1,600 patients from 231 participating
investigative sites in 13 countries. International coordinating
investigators were Pascal Demoly, Professor at the Department of
Pneumology and Addiction Heart Poumons Center at the University Hospital
of Montpellier, France, President of the College of Allergology Teachers
and President of the French Allergy Federation, and Thomas Casale, MD,
Professor of Medicine and Pediatrics at the University of South Florida.

ABOUT STALLERGENES GREER Ltd

Headquartered in London (UK), Stallergenes Greer Ltd is a global
healthcare company specializing in the diagnosis and treatment of
allergies through the development and commercialization of allergy
immunotherapy products and services. Stallergenes Greer Ltd is the
parent company of Greer Laboratories, Inc. (whose registered office is
in the United States) and Stallergenes SAS (whose registered office is
in France).